{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:53:28Z","timestamp":1757627608523,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-14861-9","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T09:15:04Z","timestamp":1756804504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Normalization of serum alpha fetoprotein after direct acting antivirals in hepatitis C patients lowers hepatocellular carcinoma risk"],"prefix":"10.1038","volume":"15","author":[{"given":"Cheng-Kuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ssu-Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzong-Hsi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"14861_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich, G. et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112, 463\u2013472 (1997).","journal-title":"Gastroenterology"},{"key":"14861_CR2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1056\/NEJM199306243282502","volume":"328","author":"Y Sato","year":"1993","unstructured":"Sato, Y. et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl. J. Med. 328, 1802\u20131806 (1993).","journal-title":"N Engl. J. Med."},{"key":"14861_CR3","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1111\/j.1572-0241.1998.00703.x","volume":"93","author":"N Bayati","year":"1998","unstructured":"Bayati, N., Silverman, A. L. & Gordon, S. C. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am. J. Gastroenterol. 93, 2452\u20132456 (1998).","journal-title":"Am. J. Gastroenterol."},{"key":"14861_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00004836-200103000-00014","volume":"32","author":"CW Chu","year":"2001","unstructured":"Chu, C. W. et al. Clinical, virological, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J. Clin. Gastroenterol. 32, 240\u2013244 (2001).","journal-title":"J. Clin. Gastroenterol."},{"key":"14861_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1572-0241.2004.04152.x","volume":"99","author":"KQ Hu","year":"2004","unstructured":"Hu, K. Q. et al. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am. J. Gastroenterol. 99, 860\u2013865 (2004).","journal-title":"Am. J. Gastroenterol."},{"key":"14861_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00535-010-0293-6","volume":"46","author":"M Tateyama","year":"2011","unstructured":"Tateyama, M. et al. \u03b1-Fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J. Gastroenterol. 46, 92\u2013100 (2011).","journal-title":"J. Gastroenterol."},{"key":"14861_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jhep.2005.03.019","volume":"43","author":"AM Di Bisceglie","year":"2005","unstructured":"Di Bisceglie, A. M. et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial. J. Hepatol. 43, 434\u2013441 (2005).","journal-title":"J. Hepatol."},{"key":"14861_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1440-1746.2007.04898.x","volume":"22","author":"TM Chen","year":"2007","unstructured":"Chen, T. M. et al. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but no hepatocellular carcinoma, and its normalization after pegylated interferon Alfa 2a-ribavirin combination therapy. J. Gastroenterol. Hepatol. 22, 669\u2013675 (2007).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"14861_CR9","first-page":"43","volume":"5","author":"K Nguyen","year":"2017","unstructured":"Nguyen, K. et al. Decrease of alpha-fetoprotein in patients with cirrhosis treated with direct-acting antivirals. J. Clin. Transl Hepatol. 5, 43\u201349 (2017).","journal-title":"J. Clin. Transl Hepatol."},{"key":"14861_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s11684-019-0707-7","volume":"13","author":"T Huynh","year":"2019","unstructured":"Huynh, T. & Hu, K. Q. Direct acting antiviral-induced dynamic reduction of serum \u03b1 fetoprotein in hepatitis C patients without hepatocellular carcinoma. Front. Med. 13, 658\u2013666 (2019).","journal-title":"Front. Med."},{"key":"14861_CR11","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal, F. et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 153, 996\u20131005 (2017).","journal-title":"Gastroenterology"},{"key":"14861_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","volume":"68","author":"GN Ioannou","year":"2018","unstructured":"Ioannou, G. N., Green, P. K. & Berry, K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J. Hepatol. 68, 25\u201332 (2018).","journal-title":"J. Hepatol."},{"key":"14861_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00535-011-0505-8","volume":"47","author":"Y Osaki","year":"2012","unstructured":"Osaki, Y. et al. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. J. Gastroenterol. 47, 444\u2013451 (2012).","journal-title":"J. Gastroenterol."},{"key":"14861_CR14","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1093\/jac\/dkw097","volume":"71","author":"CK Wu","year":"2016","unstructured":"Wu, C. K. et al. Dynamic \u03b1-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. J. Antimicrob. Chemother. 71, 1943\u20131947 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"14861_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/hep.30823","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal, F. et al. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology 71, 44\u201355 (2020).","journal-title":"Hepatology"},{"key":"14861_CR16","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","volume":"157","author":"GN Ioannou","year":"2019","unstructured":"Ioannou, G. N. et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology 157, 1264\u20131278 (2019).","journal-title":"Gastroenterology"},{"key":"14861_CR17","doi-asserted-by":"publisher","first-page":"e0243473","DOI":"10.1371\/journal.pone.0243473","volume":"15","author":"K Abe","year":"2020","unstructured":"Abe, K. et al. Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis. PLoS One. 15, e0243473 (2020).","journal-title":"PLoS One"},{"key":"14861_CR18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s12072-020-10105-2","volume":"14","author":"Y Tanaka","year":"2020","unstructured":"Tanaka, Y. et al. HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. Hepatol. Int. 14, 1023\u20131010 (2020).","journal-title":"Hepatol. Int."},{"key":"14861_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/jvh.13625","volume":"29","author":"A Kuwano","year":"2022","unstructured":"Kuwano, A. et al. Serum \u03b1-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. J. Viral Hepat. 29, 35\u201342 (2022).","journal-title":"J. Viral Hepat."},{"key":"14861_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12876-023-03099-2","volume":"24","author":"VYS Chow","year":"2024","unstructured":"Chow, V. Y. S. & Cheung, W. Evaluation of patients treated with direct\u2013acting anti\u2013viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong. BMC Gastroenterol. 24, 49 (2024).","journal-title":"BMC Gastroenterol."},{"key":"14861_CR21","doi-asserted-by":"publisher","first-page":"e0262267","DOI":"10.1371\/journal.pone.0262267","volume":"17","author":"S Mawatari","year":"2022","unstructured":"Mawatari, S. et al. Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C virus. PLoS ONE. 17, e0262267 (2022).","journal-title":"PLoS ONE"},{"key":"14861_CR22","first-page":"2205","volume":"19","author":"J Tani","year":"2020","unstructured":"Tani, J. et al. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct\u2013acting antiviral treatment: all Kagawa liver disease group study. Oncol. Lett. 19, 2205\u20132212 (2020).","journal-title":"Oncol. Lett."},{"key":"14861_CR23","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/jvh.12982","volume":"25","author":"C Masetti","year":"2018","unstructured":"Masetti, C. et al. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. J. Viral Hepat. 25, 1493\u20131500 (2018).","journal-title":"J. Viral Hepat."},{"key":"14861_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/hepr.13278","volume":"49","author":"T Watanabe","year":"2019","unstructured":"Watanabe, T. et al. Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. Hepatol. Res. 49, 136\u2013146 (2019).","journal-title":"Hepatol. Res."},{"key":"14861_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/apt.14380","volume":"47","author":"E Ogawa","year":"2018","unstructured":"Ogawa, E. et al. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct acting anti-viral treatment. Aliment. Pharmacol. Ther. 47, 104\u2013113 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"14861_CR26","doi-asserted-by":"publisher","first-page":"8992","DOI":"10.1038\/s41598-023-36052-0","volume":"13","author":"T Watanabe","year":"2023","unstructured":"Watanabe, T. et al. Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct\u2013acting antivirals. Sci. Rep. 13, 8992 (2023).","journal-title":"Sci. Rep."},{"key":"14861_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/jgh.14378","volume":"34","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka, A. et al. Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after direct acting antivirals: multicenter analysis. J. Gastroenterol. Hepatol. 34, 436\u2013441 (2019).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"14861_CR28","doi-asserted-by":"publisher","first-page":"e0195173","DOI":"10.1371\/journal.pone.0195173","volume":"13","author":"K Hamada","year":"2018","unstructured":"Hamada, K. et al. Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response. PLoS ONE. 13, e0195173 (2018).","journal-title":"PLoS ONE"},{"key":"14861_CR29","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1097\/MD.0000000000000901","volume":"94","author":"T Minami","year":"2015","unstructured":"Minami, T. et al. Serum alpha-fetoprotein has high specificity for the early detection of hepatocellular carcinoma after hepatitis C virus eradication in patients. Medicine 94, e901 (2015).","journal-title":"Medicine"},{"key":"14861_CR30","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV\/HCV co-infection. Hepatology 43, 1317\u20131325 (2006).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14861-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14861-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14861-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:12:54Z","timestamp":1757477574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14861-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14861"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14861-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to institutional and international ethical guidelines. The study protocol was reviewed and approved by the Institutional Review Board of Far Eastern Memorial Hospital (Approval No. 111125-E). Written informed consent for DAA therapy was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32312"}}